Extensive Kaposi's sarcoma in a Patient with Acquired Immunodeficiency Syndrome: Case Report

Main Article Content

David Sandoval Sánchez
Estanislao Antonio Calixto
Roberto Peralta Juárez
Marcos García Aranda
Rolando Castellanos Villalobos
Jessica Ariatna Carreto Navarrete

Abstract




Kaposi's Sarcoma (KS) is an angioproliferative neoplasm, the causative agent is human herpes virus 8 and the second most frequent tumor after non-Hodgkin lymphoma related to the human immunodeficiency virus (VIH). We present the case of a 40-year-old male with no history of chronic diseases, who began his condition with adenopathies in the bilateral inguinal region, adding a productive cough, lymphedema, and skin lesions with nodular characteristics and bleeding ulcers. A positive HIV test was reported, and a biopsy was performed, showing evidence of a spindle cell neoplasm compatible with KS. Laboratories with hemoglobin 8.3 mg/dL, platelets 239,000/uL, leukocytes 7.29/uL, glucose 76 mg/dL, creatinine 2.2 mg/dL, urea 80 mg/dL, albumin 1.69 g/dL, TGO 18 IU/L, TGP 5 IU/L, DHL 189 IU/L, viral load 283,259 copies and CD4 192 cells. Chest and abdomen computed tomography with evidence of pleural effusion, and multiple retroperitoneal and inguinal adenopathies. Starting concomitant retroviral treatment with liposomal doxorubicin, improving clinical status and laboratory parameters. HIV-infected people are at high risk of developing KS, early initiation of antiretroviral therapy, and maintenance of high CD4 cell counts are essential to reduce the incidence.




Article Details

How to Cite
Sandoval Sánchez, D. ., Antonio Calixto, E., Peralta Juárez, R. ., García Aranda, M. ., Castellanos Villalobos, R. ., & Carreto Navarrete, J. A. (2023). Extensive Kaposi’s sarcoma in a Patient with Acquired Immunodeficiency Syndrome: Case Report. International Journal of Medical Science and Clinical Research Studies, 3(1), 68–70. https://doi.org/10.47191/ijmscrs/v3-i1-14
Section
Articles

References

I. Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers 2019;5(1):9.

II. Dupin N. Update on oncogenesis and therapy for Kaposi sarcoma. Curr Opin Oncol 2020; 32(2):122–8.

III. Etemad SA, Dewan AK. Kaposi sarcoma updates. Dermatol Clin 2019;37(4):505–17.

IV. Schneider JW, Dittmer DP. Diagnosis and treatment of Kaposi sarcoma. Am J Clin Dermatol 2017;18(4):529–39.

V. Lebbe C, Garbe C, Stratigos AJ, Harwood C, Peris K, Marmol VD, et al. Diagnosis and treatment of Kaposi’s sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer 2019;114:117–27.

VI. Curtiss P, Strazzulla LC, Friedman-Kien AE. An update on Kaposi’s sarcoma: Epidemiology, pathogenesis and treatment. Dermatol Ther (Heidelb). 2016; 6(4): 465–70.

VII. Rusu ZG, Manole OM, Gales C, Porumb AE, Obadă O, Mocanu CV. Kaposi sarcoma, a trifecta of pathogenic mechanisms. Diagnostics (Basel). 2022;12 (5): 1242.

VIII. AIDS-defining Cancer Project Working Group for IDEA and COHERE in EuroCoord. Comparison of Kaposi sarcoma risk in human immunodeficiency virus-positive adults across 5 continents: a multiregional multicohort study. Clin Infect Dis. 2017 Oct 15; 65(8) :1316-1326.

IX. Ferla LL, Costantino LP, Mondello P. Kaposi's sarcoma in HIV-infected patients: a review of the literature. Infect Dis Trop Med 2016; 2(1):E239.

X. Addula D, Das CJ, Kundra V. Imaging of Kaposi sarcoma. Abdom Radio (NY). 2021:46:5297-306.

XI. Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE. Treatment of severe or ptogressive Kaposi's sarcoma in HIV-infected adults. Cochrane Database Syst Rev 2014;CD003256.

XII. Thieringer FM, Cede J, Glatz K, Roehling S, Stoeckle M, Leiggener CS. Oral Kaposi's sarcoma: a case report and literature review on treatment management. Craniomaxillofacial Trauma & Reconstruction Open. 2021; 6:1-7.

Most read articles by the same author(s)

<< < 1 2